VANCOUVER, BC / ACCESSWIRE / March 4, 2019 / With favorable cannabis-growing conditions, Colombia is quickly emerging as an industry hot spot. In fact, the country could capture as much as a fifth of a global market that could be worth $40 billion a year, according to Reuters.
"Colombia is wooing foreign investors, talking up its potential in the new era of peace as a resource-rich country with a business-friendly regulatory environment," noted The Globe and Mail. "Colombia has the ideal climate for cannabis, with the evenly split 12 hours of light and dark each day that the plant prefers, a pool of low-cost labor and easily-transferable expertise and infrastructure from a large cut-flower export business."
That could be quite beneficial to several cannabis stocks with exposure including Blueberries Medical Corp. (CSE:BBM)(OTC PINK:BBRRF), Khiron Life Sciences Corporation (KHRNF) (KHRN), and PharmaCielo Ltd. (PHCEF)(PCLO).
Colombian-based producer, Blueberries Medical Corp (BBM), for example, just announced its common shares are now listed on the Frankfurt Stock Exchange (FSE) trading under the ticker symbol "1OA". The stock will also continue to list on the Canadian Stock Exchange and on the OTC in the United States.
"Listing on the Frankfurt Stock Exchange is an important milestone for Blueberries, consistent with our global strategy which includes exports to the European market," stated Camilo Villalba, Chief Operating Officer. "It will allow us to broaden our shareholder base to include more investors based in Europe as cannabis markets continue to expand globally."
The company also just entered into a letter of intent for a joint venture with India Colorada S.A.S., a leading Colombian brewer and producer of Cerveza Colón, to research, develop and commercialize non-alcoholic cannabis-based beverages. "As consumer preferences continue to evolve away from smoked flower and towards healthier and more convenient products, we plan to be on the leading edge of innovating and commercializing these new product segments," stated Camilo Villalba, BBM COO, noted.
For More Information on Blueberries Medical Corp., Click Here.
Analysts at Canaccord Genuity raised their price target on Khiron Life Sciences Corporation (KHRN)(KHRNF) to C$6.50 a share. "In our view, the company has a significant number of potential catalysts that should keep share price momentum going. Commercial sales of medical CBD products are expected in the early part of Q2, while a generous commercial THC quote toward mid-year could further validate Khiron's distribution strategy," the analysts noted.
"The passing of Mexican medical and recreational cannabis laws (likely in Q2) are also significant potential catalysts and we note that the company is co-hosting a large cannabis conference, CannaMexico, April 25-26."
For More Information on Khiron Life Sciences Corporation, Click Here.
Analysts at GMP just initiated coverage on PharmaCielo Ltd. (PHCEF)(PCLO) with a Buy rating and a price target of C$12. They also note that PCLO is the best pure-play on the global CDB market. "We consider PCLO to be the most advanced Colombian licensed producer currently, providing a ~6—18 month first-mover advantage over nearly all Colombian competitors. In addition, with CBD extract capacity expected to reach ~17 tonnes in 2019, we believe this qualifies PCLO as the largest international publicly-traded producer."
"With favorable Colombian regulations, we estimate PCLO could have CBD yields ~250x—300x higher than those available to global peers. We believe PCLO could achieve CBD extract production costs as low as ~$0.15—0.25/gram, potentially the lowest globally."
For More Information on PharmaCielo Ltd., Click Here.
Legal Disclaimer / Nothing in this article should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this article is not provided to any individual with a view toward their individual circumstances. Baystreet.ca has been paid a fee of four thousand five hundred dollars for Blueberries Medical Corp. advertising. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this article as the basis for any investment decision. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this article is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
CONTACT:
Aaron Bodnar
aaron@baystreet.ca
SOURCE: Baystreet.ca Media Corp.